CENTESSA-Icon-Logo

Carol Stuckley MBA

Carol Stuckley, MBA is a global, strategic financial executive with proven success leading finance teams and creating shareholder value for healthcare companies.

Carol recently served as Chief Financial Officer and Senior Vice President at Healthcare Payment Specialists, LLC, leading to its acquisition by TransUnion, Inc. Her previous roles include Vice President, Finance North America of Galderma Laboratories, L.P. (Nestle Skin Health), and during her close to 23-year global career at Pfizer, Inc., she most recently served as Vice President, Assistant Treasurer and Corporate Officer.

Carol currently serves on the board of Transgene, a French biotechnology company traded on the Euronext (Paris) exchange. She previously served on the board of Epizyme, Inc., a US biopharmaceutical company traded on NASDAQ, and on the board of Ipsen S.A., a French pharmaceutical company traded on the Euronext (Paris) exchange. During her tenure at Pfizer, she served on several Pfizer Luxembourg company boards.

Carol holds a Master of Arts in Economics and an MBA in International Finance from Temple University’s Fox Business School and a BA with Distinction in Economic and French from the University of Delaware.

Back to Board of Directors
Scroll to Top
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678, NCT05789524, NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B